Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Abstract

is a principal investigator and advisory board member for AbbVie; is an advisory board member for Eli Lilly; is a principal investigator for LEO Pharma; is a principal investigator and advisory board member for Pfizer; is a principal investigator, provides research support, has received honoraria for lecturing, and is an advisory board member and consultant for Regeneron Pharmaceuticals and Sanofi Genzyme; and is an advisory board member for UCB. Dr Blauvelt is a scientific advisor and clinical study investigator for

Treatment of epidermolysis bullosa pruriginosa‐associated pruritus with dupilumab

“…Dupilumab is a fully humanized monoclonal antibody targeting the interleukin‐4 receptor alpha (IL‐4Rα), a receptor subunit shared by two type 2 cytokines, IL‐4 and IL‐13, which play an important role in the pathogenesis of atopic dermatitis. Besides being an effective treatment for atopic dermatitis, dupilumab has been shown to be effective for the treatment of generalized pruritus and prurigo nodularis in several recent reports, suggesting that it may possibly benefit patients with EBP.…”

The Challenge of Hand Eczema: Pathogenesis, Treatment, and Burden of Disease

“…Therefore, possibly other cytokine profiles result into palmar hyperkeratosis in HHE. 40,41,48,50,53 Hereditary PPK is another group of skin diseases with palmar hyperkeratosis, which provides more insight about the association of different keratins, desmosomal proteins and epidermal barrier proteins to palmoplantar hyperkeratosis. [8][9][10][54][55][56][57][58] In this study no monogenetic mutations related to palmar hyperkeratosis were found.…”

“…Alitretinoin was studied in large randomized controlled trials with more than 1600 participants and showed positive effects on all hand eczema subtypes. [51][52][53] Treatment with 30 mg/day of alitretinoin resulted in clear or almost clear hand eczema in 48% of the participants, compared Vesicular eruptions on the palms and/or sides of the fingers. Eruptions may occur at intervals of weeks of months and may be so frequent that a chronic eczema is seen.…”

“…52 The best therapeutic effects were found for the hyperkeratotic subtypes. [52][53][54] Evidence about effectiveness of other systemic hand eczema treatments is scarce, and large randomized controlled trials are lacking. 29,54 Regularly used off-label treatment alternatives for severe hand eczema are systemic corticosteroids, azathioprine, 55 methotrexate, 56,57 acitretin [58][59][60] and, more recently, dupilumab.…”

“…Dupilumab is a human monoclonal antibody inhibiting interleukin (IL) 4 and IL-13 signaling, and has been successfully approved for the treatment of moderate-to-severe atopic dermatitis. 52,53 It has also shown promising perspectives in small observational studies in patients with difficult to treat atopic hand eczema. 38,54,55 Moreover, case studies in non atopic individuals with isolated recurrent vesicular (n=16) and chronic fissured hand eczema (n=1) have reported substantial beneficial effects of dupilumab.…”